Pyridazine Compounds as NLRP3 Inhibitors for Treating Parkinson's Disease or Frontotemporal Dementia.

ACS Med Chem Lett

Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.

Published: December 2024

Provided herein are novel pyridazine compounds as NLRP3 inhibitors, pharmaceutical compositions, use of such compounds in treating Parkinson's disease or frontotemporal dementia, and processes for preparing such compounds.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11647718PMC
http://dx.doi.org/10.1021/acsmedchemlett.4c00523DOI Listing

Publication Analysis

Top Keywords

pyridazine compounds
8
compounds nlrp3
8
nlrp3 inhibitors
8
treating parkinson's
8
parkinson's disease
8
disease frontotemporal
8
frontotemporal dementia
8
inhibitors treating
4
dementia provided
4
provided novel
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!